Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
Status:
RECRUITING
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (S-1+Oxaliplatin) and radiotherapy for locally advanced esophagogastric junction adenocarcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology